The association between inherited metabolic disorders and the sudden infant death syndrome (SIDS) 
The association between inherited metabolic disorders and the sudden infant death syndrome (SIDS) received considerable attention in the mid to late 1980s. The earlier reports suggested that as many as 5-10% of all cases of SIDS in the UK could be due to metabolic disorders.' 2 More recent publications, however, suggest a more conservative estimate that such disorders probably account for fewer than 3% of all cases of SIDS-5 and thus compare better with the recurrence risk of 2% quoted in several studies. 6 The only group of inherited metabolic disorders for which there is good evidence that they are responsible for SIDS are those of fatty acid oxidation. The evidence that other inborn errors can present as SIDS is scanty,78 although many defects have the potential to cause unexpected infant death. 9 Despite the rarity of these disorders it is important to identify those cases where an inherited defect is the likely cause or contributes to the cause of death or a near miss death in infancy. In SIDS. 18 Finally, disorders of carnitine metabolism or carnitine deficiency resulting in impaired fatty acid oxidation are potential causes of SIDS.
In summary therefore there are a whole range of fatty acid oxidation defects which can present as SIDS. Urinary organic acid analysis using gas chromatography-mass spectrometry will detect most of these cases in symptomatic patients but may miss the diagnosis in a well child. Enzyme assays or DNA analysis are required for definitive diagnosis and are specific for a particular defect or group of disorders.
GLYCOGEN STORAGE DISEASE
Glycogen storage disease type I is a group of disorders due to deficiency of the hepatic microsomal glucose-6-phosphatase system.'9 The glucose-6-phosphatase system is a complex multicomponent enzyme system and several different disorders can occur (types Ia, Ib, Ic, and Id), depending on the exact location of the defect. Classical glucose-6-phosphatase deficiency is now termed type Ia glycogen storage disease.
The finding of glycogen storage diseases types Ia, Ib, and Ic in tissues from patients with SIDS has been reported78 and it was suggested that glucose-6-phosphatase deficiency may be a significant cause of SIDS.
The cases reported by Burchell et al, however, were highly selected and more recent data have suggested an alternative explanation for these findings.20 Liver glucose-6-phosphatase activity at birth is about 10% of adult values. In infants born at term the activity rises rapidly after delivery to reach adult values by about 3 days of age. In premature infants this postnatal surge may not occur and glucose-6-phosphatase activity may remain low compared with their normal term counterparts. This apparent failure to switch on glucose-6-phosphatase activity results in impaired mechanisms for maintaining blood glucose homoeostasis. Preliminary results from studies with an animal model suggest that the hormonal and nutritional environment in the perinatal period are critical to the normal development of the glucose-6-phosphatase system. It seems likely therefore that physiological and/or environmental effects on liver glucose-6-phosphatase activity may explain a large percentage of the earlier findings rather than a primary genetic defect.
At present the contribution of the various inherited defects of the glucose-6-phosphatase system as causes of SIDS is unknown. Although there is a suspicion that they may contribute to the causes of SIDS, more research and larger studies are required to produce meaningful incidence data.
OTHERS
Several other inherited metabolic disorders including congenital adrenal hyperplasia, systemic carnitine deficiency, biotinidase deficiency, and maple syrup urine disease can present as sudden, unexpected death. In most cases reported there has usually been a preceeding history of some note. Other disorders including the electron transport chain disorders and disorders of pyruvate metabolism are likely to be included in this group.
A previous history of developmental delay and/or seizures and sudden death after fasting or other catabolic stress such as infection, immunisations, or fever should suggest an inherited defect.
Diagnosis of metabolic disorders INVESTIGATION POSTMORTEM
The possibility of an inherited metabolic disorder should be considered by the pathologist in all cases of SIDS and especially in those cases of sudden unexpected death in infancy where there has been significant prodromal symptoms. A previous clinical history and or a family history in which more than one infant appears to have died suddenly of unknown cause are among those more likely to have a metabolic cause.
A prompt and careful postmortem examination by a paediatric pathologist with sampling of tissues as quickly as possible after death and appropriate storage at -70°C or below is essential for meaningful biochemical studies. Suitable approaches to sampling for investigation of metabolic disorders have been detailed.9'2
The finding of panlobular fatty change in the liver or fatty change in other tissues (heart, skeletal, muscle) or excess glycogen storage are suggestive ofan inherited metabolic disorder and should initiate further metabolic studies. However, the absence of significant fatty infiltration ofthe liver in a family with a history suggestive of a metabolic disorder should not deter further investigations. 22 For the majority of cases of SIDS, however, there are no clues from the history or postmortem examination and further metabolic studies are unlikely to be carried out.
HOW TO DIAGNOSE THESE DISORDERS IN ASYMPTOMATIC SIBLINGS
Fatty acid oxidation defects Fatty acid oxidation defects are detected by the finding of abnormal amounts of dicarboxylic acids and their metabQlites in urine. These characteristic findings are present when the child is symptomatic/stressed but may be absent when well. The baby with one of these defects may show abnormalities in the early neonatal period when subject to catabolic stresses. 2 As part of a national CONI (care of next infant) study into cot deaths, a research project into neonatal screening of siblings by urinary organic acids has been undertaken in Sheffield. Results from the study have shown that screening newborns during the first 72 hours of life for fatty acid oxidation defects is feasible provided that gas chromatography-mass spectrometry is used (R J Pollitt, personal communication). Urinary organic acid screening is, however, a highly complex investigation and normal babies, without proved defects of fatty acid oxidation, can excrete large quantities of dicarboxylic acids. These findings can be difficult or impossible to differentiate from those found in some types of fatty acid oxidation disorders. The results emphasise the importance of skilled interpretation of urinary organic acids and the difficulties in making a definitive diagnosis based on metabolite profiles. The advantage, however, of the urinary organic acid profile is that it is a nonspecific approach and is capable of detecting a whole range of inborn errors, not only the fatty acid defects.
An alternative approach is to diagnose the fatty acid oxidation defects by specific enzyme or molecular studies. Enzyme assays, however, require tissue (cultured skin fibroblasts/liver/ muscle) and the specialist assays are complex and available in only a handful of centres in the UK. They are not suitable methods for screening. Molecular studies on DNA from blood or tissue will detect specific mutations and currently are applicable only to MCAD. In view of the probable high incidence of MCAD in white populations, and the ability to intervene and influence morbidity and mortality, whole population neonatal screening of MCAD using the neonatal Guthrie blood spot system has been suggested. Specimen requirements A fresh random urine (no preservatives) is required (ideally 5 ml). Specimens should be stored deep frozen as soon as possible after collection and transported to the laboratory deep frozen. The request should be sent to a specialist laboratory with expertise in gas chromatographymass spectrometry*. The request should be made specific -MCAD deficiency -and full details of SIDS history should be provided. A 'standard' urinary organic acid investigation may not include gas chromatography-mass spectrometry analysis for the specific metabolites found in MCAD and therefore may miss the diagnosis.
Blood (5 ml collected in EDTA) for carnitine and DNA (some laboratories may be able to perform this investigation on a Guthrie blood spot) should be sent to a specialist laboratory undertaking these tests; the laboratory performing organic acid measurements should be able to advise on where these tests are available. 
Conclusion

